CPD704

CPD704 is an investigational small molecule Janus kinase (JAK) inhibitor developed by Beijing Tide Pharmaceutical, a subsidiary of Sino Biopharmaceutical. It is formulated as an inhalation suspension designed for localized delivery to the lungs via a nebulizer. The drug aims to treat chronic inflammatory and fibrotic respiratory conditions, such as asthma, chronic obstructive pulmonary disease (COPD), and idiopathic pulmonary fibrosis (IPF). By delivering the JAK inhibitor directly to the site of inflammation, CPD704 is intended to maximize therapeutic efficacy in the airways while minimizing the systemic exposure and associated side effects often seen with oral JAK inhibitors.

Other names

CPD704 Inhalation SuspensionCPD-704 Inhalation SuspensionCPD 704 Inhalation Suspension